Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 43 Metastatic Castration-resistant Prostate Cancer 5 Prostatic Diseases 3 Kidney Neoplasms 3 Urogenital Neoplasms 2 Prostatic Neoplasms, Castration-Resistant 2 Neoplasms by Site 2 Neoplasms 2 Genital Neoplasms, Male 2 Carcinoma, Renal Cell 2 Thrombocytopenia 1 Renal Insufficiency 1 Prostate Cancer Metastatic 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Neoplasm Metastasis 1 Metastatic Hormone Naive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Metastatic Castration Resistant Prostate Cancer 1 Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1 Male Urogenital Diseases 1 Liver Neoplasms 1 High-Risk Localized Prostate Cancer 1 Glioma 1 Glioblastoma 1 Genital Diseases, Male 1 Disease 1 Cytopenia 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 157 Gemcitabine 140 Capecitabine 123 Paclitaxel 121 Fluorouracil 117 Oxaliplatin 110 Bevacizumab 106 Nivolumab 99 Docetaxel 98 Leucovorin 97 Cisplatin 90 Radiosurgery 88 Irinotecan 88 Carboplatin 86 Cyclophosphamide 72 Cetuximab 72 Magnetic Resonance Spectroscopy 68 Specimen Handling 60 Radiotherapy 60 Trastuzumab 59 Biopsy 59 Ipilimumab 53 Drug Therapy 51 Everolimus 48 Pemetrexed 46 Albumin-Bound Paclitaxel 45 130-nm albumin-bound paclitaxel 44 Doxorubicin 42 Fulvestrant 40 aldesleukin 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × Pluvicto × Clear all

NCT03392428 2022-06-13

TheraP

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Completed

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡